tyrosine kinase inhibitor inhibitors tki therapy prior treatment bruton egfr 
egfr tki treatment tm mutation erlotinib prior generation progression gefitinib 
philadelphia chromosome ph positive abl kinase bcr tyrosine patients tki 
egfrmut antineoplastic tm met phase egfr ii group tki nave